Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease.
about
Rho family GTPases: key players in neuronal development, neuronal survival, and neurodegenerationCross-talk of membrane lipids and Alzheimer-related proteins.Molecular mechanisms underlying the effects of statins in the central nervous system.Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disordersEmerging therapeutics for Alzheimer's disease: an avenue of hope.Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease.Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations.Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component.Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia.Cholesterol, statins and tau.Lovastatin inhibits amyloid precursor protein (APP) beta-cleavage through reduction of APP distribution in Lubrol WX extractable low density lipid rafts.A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism.Mild cholesterol depletion reduces amyloid-beta production by impairing APP trafficking to the cell surface.Diet and age interactions with regards to cholesterol regulation and brain pathogenesis.Cholesterol: a novel regulatory role in myelin formation.Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.The Role of Geranylgeranyltransferase I-Mediated Protein Prenylation in the Brain.Lovastatin Differentially Affects Neuronal Cholesterol and Amyloid-β Production in vivo and in vitro.Association of Long-Term Atorvastatin with Escalated Stroke-Induced Neuroinflammation in Rats.Simvastatin interferes with process outgrowth and branching of oligodendrocytes.TDP-43 depletion induces neuronal cell damage through dysregulation of Rho family GTPases.Inhibition of Rac GTPase triggers a c-Jun- and Bim-dependent mitochondrial apoptotic cascade in cerebellar granule neurons.Inhibiting geranylgeranyltransferase I activity decreases spine density in central nervous system.The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease.Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia.Geranylgeranyl pyrophosphate is crucial for neuronal survival but has no special role in Purkinje cell degeneration in Niemann Pick type C1 disease.Rho family GTPase inhibition reveals opposing effects of mitogen-activated protein kinase kinase/extracellular signal-regulated kinase and Janus kinase/signal transducer and activator of transcription signaling cascades on neuronal survival.Differential roles of the mevalonate pathway in the development and survival of mouse Purkinje cells in culture.A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Postischemic Brain Injury.Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease.
P2860
Q27027490-EB2A5A74-DF89-41E6-9CC2-BE61322BDAA3Q33592538-F612AF99-8249-4248-9BD9-7559678C2020Q34685463-3A1CF851-151C-4B8F-BF24-BFCA3BFB6BFEQ35087574-28620816-6789-482A-9ED4-FE3DAC490248Q35618922-9917CBFF-30A4-4305-BD6F-7A4A7565A2BFQ35634151-0F2A3D6F-E6A9-4804-A137-DF6139BEEB39Q35642416-0DD05E4C-FAB5-42FA-80B5-3EAB13A1EAFEQ35841700-B1D80840-D114-4F15-80FE-811176609466Q35976397-A44D6ED6-EF24-47C5-916B-CDD65397EEECQ36546527-CAD7DF6A-1776-4614-B6E3-9399D8BA8178Q37254798-361E59AF-F2CF-40B2-8E10-75109D362A2DQ37285877-A8049F2D-7F6F-42B5-B8E6-607B6AA3BE6EQ37341916-CB26CE0D-C8DA-41C3-A47F-A75B10AA3BAFQ37731946-01F42FB7-5651-4E42-8330-94622A3847B7Q37846006-2F2128FA-7561-416A-B112-CB16E1408172Q38179262-00DDB3A7-5300-40E9-BFC2-AECCF4E5DAB3Q38669055-15C19B93-7675-44DB-8E96-8BC87CAAEB3CQ38861519-A4447F80-1ECA-4275-8D03-32B601776BA3Q39474081-F02F43F9-442C-4FA0-B140-05D96264CC56Q39653271-A6473EF4-ADFD-4FB8-85CE-CA4CED603B81Q39836728-194C9DD2-513E-4F40-BC96-5263216E0EF6Q42072153-7828F57D-B705-4D08-B20F-D7B8B3671083Q42467429-5DCDBE1E-7845-442F-8C9F-B5BEF40F455AQ42651492-7032F0F2-2091-4AC6-85D1-86B3832770AEQ45057128-F6BB3C8E-BCA9-4827-900F-068E5C7AFF59Q48484002-A44C7070-25F0-4DC1-A55A-0321F738ED90Q48547144-B49992EB-EC3A-49FC-9EF4-7F2EA6034C9FQ48690287-0556FC04-456B-488E-A7A9-5E6A0EBC34A9Q52091138-71242900-61E0-4CBA-9946-C2FE7C893ACFQ54223105-DBE88D25-66ED-4974-9127-7EFFF728ADD3
P2860
Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Blockade of HMG-CoA reductase ...... tions for Alzheimer's disease.
@en
Blockade of HMG-CoA reductase ...... tions for Alzheimer's disease.
@nl
type
label
Blockade of HMG-CoA reductase ...... tions for Alzheimer's disease.
@en
Blockade of HMG-CoA reductase ...... tions for Alzheimer's disease.
@nl
prefLabel
Blockade of HMG-CoA reductase ...... tions for Alzheimer's disease.
@en
Blockade of HMG-CoA reductase ...... tions for Alzheimer's disease.
@nl
P2093
P2860
P1476
Blockade of HMG-CoA reductase ...... tions for Alzheimer's disease.
@en
P2093
P2860
P304
P356
10.1046/J.1460-9568.2003.02433.X
P407
P577
2003-01-01T00:00:00Z